Titre:
  • Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Auteur:Subbiah, Vivek; Paz Ares, Luis; Besse, Benjamin; Moreno, Victor; Peters, Solange; Sala, María Angeles; López-Vilariño, José Antonio; Fernández, Cristian; Kahatt, Carmen; Alfaro, Vicente; Siguero, Mariano; Zeaiter, Ali; Zaman, Khalil; López, Rafael; Ponce, Santiago; Boni, Valentina; Arrondeau, Jennifer; Delord, Jean Pierre; Martínez, Maite; Wannesson, Luciano; Anton, Antonio; Valdivia, Javier; Awada, Ahmad; Kristeleit, Rebecca; Olmedo, Maria Eugenia; Rubio, María Jesús; Sarantopoulos, John; Chawla, Sant; Mosquera-Martinez, Joaquín; D’ Arcangelo, Manolo; Santoro, Armando; Villalobos, Victor Manuel; Sands, Jacob; Trigo, José
Informations sur la publication:Lung cancer, 150, page (90-96)
Statut de publication:Publié, 2020-12
Sujet CREF:Cancérologie
Pneumologie
Mots-clés:Chemotherapy-free interval
Lurbinectedin
NCCN guidelines
Platinum re-challenge
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0169-5002
info:doi/10.1016/j.lungcan.2020.10.003
info:pii/S0169500220306401
info:scp/85092925317